Immutep Limited Share Price
Stocks
IMM
AU000000IMM6
Biotechnology & Medical Research
OTC Markets Traded|
Market Closed -
Australian S.E.
10:40:10 19/10/2026 am IST
|
5-day change | 1st Jan Change | ||
| 0.0230 AUD | 0.00% |
|
-11.54% | -94.46% |
| 17/09 | Immutep refocuses efti development on head and neck cancer and soft tissue sarcoma | FI |
| 15/09 | Immutep's Drug Candidate Now Has Clearer Potential Development Path, Jefferies Says | MT |
| Market Cap | 3.39Cr 2.37Cr 2.11Cr 1.95Cr 1.78Cr 3.33Cr 224.42Cr 23Cr 9.22Cr 117.29Cr 8.88Cr 8.69Cr 374.95Cr | P/E 2027 * |
-1.35x | P/E 2028 * | -2.09x |
|---|---|---|---|---|---|
| Enterprise Value | -2.07Cr -1.45Cr -1.29Cr -1.19Cr -1.09Cr -2.04Cr -137.08Cr -14Cr -5.63Cr -72Cr -5.42Cr -5.31Cr -229.03Cr | EV / Sales 2027 * |
-5.18x | EV / Sales 2028 * | 0.02x |
| Free-Float |
96.87% | Yield 2027 * |
-
| Yield 2028 * | - |
| Markets | Quality | ||
|---|---|---|---|
Australian S.E.
| IMM | Delayed | |
Tradegate
| YP1B | Real-time | |
|
OTC Markets
| PRRUF | Delayed | |
|
Deutsche Boerse AG
| YP1B | Delayed | |
|
Börse Stuttgart
| YP1B | Delayed | |
|
Boerse Muenchen
| YP1B | Real-time |
| 1 week | -11.54% | ||
| Current month | -32.35% | ||
| 1 month | -39.47% | ||
| 3 months | -54.00% | ||
| 6 months | -66.67% | ||
| Current year | -94.46% |
| 1 week | 0.02 |  | 0.03 |
| 1 month | 0.02 | | 0.04 |
| Current year | 0.02 | | 0.47 |
| 1 year | 0.02 | | 0.47 |
| 3 years | 0.02 | | 0.48 |
| 5 years | 0.02 | | 0.71 |
| 10 years | 0.02 | | 0.72 |
| Manager | Title | Age | Since |
|---|---|---|---|
Marc Voigt
CEO | Chief Executive Officer | 53 | 09/07/2014 |
David Fang
DFI | Director of Finance/CFO | - | 01/03/2018 |
Stephan Winckels
CTO | Chief Tech/Sci/R&D Officer | - | 01/07/2025 |
| Director | Title | Age | Since |
|---|---|---|---|
Marc Voigt
BRD | Director/Board Member | 53 | 09/07/2014 |
Russell Howard
CHM | Chairman | 76 | 17/11/2017 |
Frédéric Triebel
BRD | Director/Board Member | 71 | 13/09/2022 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 01/10/26 | Exercice | Director | -3,88,889 | 0.0264% | ||
| 01/10/26 | Exercice | Director | 3,88,889 | 0.0264% | ||
| 18/03/26 | Other | Chief Technology Officer | 1,42,24,374 | 0.9652% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 0.00% | -11.54% | -92.46% | -91.64% | 2.36Cr | |
| +1.52% | -7.16% | +51.66% | +67.41% | 6.5TCr | |
| +1.52% | +6.83% | +10.89% | +79.30% | 5.12TCr | |
| +0.30% | -0.46% | -0.03% | +61.89% | 5.12TCr | |
| -0.83% | +0.96% | +24.85% | +41.76% | 4.39TCr | |
| +0.77% | +6.06% | +16.65% | +134.21% | 4.2TCr | |
| +2.45% | -6.23% | +236.74% | +527.16% | 3.81TCr | |
| +2.16% | +10.36% | +18.92% | +59.70% | 3.32TCr | |
| -0.90% | -10.49% | +37.09% | +1.80% | 2.52TCr | |
| +1.60% | +2.21% | +27.96% | +28.00% | 2.25TCr | |
| Average | +0.81% | -1.03% | +33.23% | +90.96% | 3.72TCr | |
| Weighted average by Cap. | +0.93% | +0.04% | +45.45% | +112.36% |
| 2027 * | 2028 * | |
|---|---|---|
| Net sales | 40L 27.93L 24.9L 23.07L 20.97L 39.35L 26Cr 2.77Cr 1.09Cr 14Cr 1.05Cr 1.03Cr 44Cr | 30L 20.95L 18.67L 17.3L 15.73L 29.51L 20Cr 2.07Cr 81.59L 10Cr 78.6L 76.96L 33Cr |
| Net income | -2.61Cr -1.82Cr -1.62Cr -1.51Cr -1.37Cr -2.57Cr -172.8Cr -18Cr -7.1Cr -90Cr -6.84Cr -6.7Cr -288.72Cr | -3.05Cr -2.13Cr -1.9Cr -1.76Cr -1.6Cr -3Cr -201.76Cr -21Cr -8.29Cr -105.45Cr -7.98Cr -7.82Cr -337.11Cr |
| Net Debt | -5.46Cr -3.81Cr -3.4Cr -3.15Cr -2.86Cr -5.37Cr -361.49Cr -38Cr -15Cr -188.94Cr -14Cr -14Cr -603.99Cr | -3.38Cr -2.36Cr -2.11Cr -1.95Cr -1.77Cr -3.33Cr -224Cr -23Cr -9.2Cr -117.08Cr -8.86Cr -8.68Cr -374.26Cr |
| Date | Price | Change | Volume |
|---|---|---|---|
| 19/26/19 | A$0.0230 | 0.00% | 57,63,289 |
| 16/26/16 | A$0.0230 | 0.00% | 33,93,799 |
| 15/26/15 | A$0.0230 | -8.00% | 1,19,87,136 |
| 14/26/14 | A$0.0250 | -3.85% | 91,83,279 |
| 13/26/13 | A$0.0260 | -3.70% | 52,88,830 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- IMM Stock
Select your edition
All financial news and data tailored to specific country editions
